Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA-type glutamate receptors. It was first synthesized by Eli Lilly and Company in 1968. Memantine is marketed under the brands Axura and Akatinol by Merz, Namenda by Forest, Ebixaand Abixa by Lundbeck and Memox by Unipharm.
International Trial Study is Enrolling Children with Autism
A global clinical trial involving South Florida children is studying a drug that — if proven safe and effective — would deliver a dose of hope to the autism community.
ConnectMe, an international initiative with more than 85 study centers in the United States and 185 worldwide, is investigating the effects of memantine on children with autism, Asperger’s and atypical autism(also called pervasive developmental disorder not otherwise specified, or PDD-NOS). The hope is it will help treat the communication and social limitations at the heart of these disorders.
Billed as the largest study of its kind, ConnectMe is now enrolling South Florida children, according to Forest Laboratories Inc., the New York City-based pharmaceutical company leading the study.
If it’s shown to convincingly and safely improve trial participants’ impairments in interacting and communicating with others, researchers would seek the FDA’s nod as the first drug approved for offsetting autism’s core effects, said Dr. Peter Ventre, co-owner and principal investigator for Research Centers of America in Oakland Park, which is leading the study in South Florida.
More @ http://specialedpost.com/2012/10/21/international-trial-study-is-enrolling-children-with-autism/